Amexdrug Corporation
Amexdrug Corporation, a pharmaceutical and cosmeceutical company, through its subsidiaries, primarily distributes pharmaceutical products. It is also involved in the research, development, manufacture, and sale of pharmaceutical drugs, cosmetics, and medical devices. The company operates in two segments, Distribution and Health and Beauty Products. In addition, it engages in the distribution of p… Read more
Amexdrug Corporation (AXRX) - Total Liabilities
Latest total liabilities as of June 2025: $609.68K USD
Based on the latest financial reports, Amexdrug Corporation (AXRX) has total liabilities worth $609.68K USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Amexdrug Corporation - Total Liabilities Trend (1999–2024)
This chart illustrates how Amexdrug Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Amexdrug Corporation Competitors by Total Liabilities
The table below lists competitors of Amexdrug Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
ICFG Limited
LSE:ICFG
|
UK | GBX207.19 Million |
|
STRATEX INTL
BE:S1Y
|
Germany | €607.00K |
|
China Marine Food Gr
PINK:CMFO
|
USA | $154.77 Million |
|
Solartron PCL
STU:TUU
|
Germany | €1.10 Billion |
|
Inspirit Energy Holdings Plc
LSE:INSP
|
UK | GBX860.00K |
Liability Composition Analysis (1999–2024)
This chart breaks down Amexdrug Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Amexdrug Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Amexdrug Corporation (1999–2024)
The table below shows the annual total liabilities of Amexdrug Corporation from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $720.82K | +1.99% |
| 2023-12-31 | $706.74K | -42.52% |
| 2021-12-31 | $1.23 Million | -43.69% |
| 2020-12-31 | $2.18 Million | +80.86% |
| 2019-12-31 | $1.21 Million | -29.17% |
| 2018-12-31 | $1.70 Million | +13.04% |
| 2017-12-31 | $1.51 Million | -7.44% |
| 2016-12-31 | $1.63 Million | +38.32% |
| 2015-12-31 | $1.18 Million | +36.01% |
| 2014-12-31 | $865.93K | -56.22% |
| 2012-12-31 | $1.98 Million | +58.23% |
| 2011-12-31 | $1.25 Million | +14.56% |
| 2010-12-31 | $1.09 Million | +48.48% |
| 2009-12-31 | $734.81K | +12.19% |
| 2008-12-31 | $655.00K | +0.31% |
| 2007-12-31 | $653.00K | +40.73% |
| 2006-12-31 | $464.00K | +2.65% |
| 2005-12-31 | $452.00K | -9.60% |
| 2004-12-31 | $500.00K | -28.88% |
| 2003-12-31 | $703.00K | -56.25% |
| 2002-12-31 | $1.61 Million | -16.43% |
| 2001-12-31 | $1.92 Million | +27371.43% |
| 1999-12-31 | $7.00K | -- |